Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Harvard Bioscience (HBIO) Long-Term Debt Issuances (2016 - 2021)

Harvard Bioscience (HBIO) has disclosed Long-Term Debt Issuances for 11 consecutive years, with $1.8 million as the latest value for Q4 2021.

  • On a quarterly basis, Long-Term Debt Issuances fell 96.62% to $1.8 million in Q4 2021 year-over-year; TTM through Dec 2021 was $59.4 million, a 3.93% increase, with the full-year FY2021 number at $4.2 million, down 93.07% from a year prior.
  • Long-Term Debt Issuances was $1.8 million for Q4 2021 at Harvard Bioscience, down from $2.5 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $67.0 million in Q1 2018 to a low of -$100000.0 in Q4 2018.
  • A 5-year average of $9.8 million and a median of $1.9 million in 2019 define the central range for Long-Term Debt Issuances.
  • Biggest YoY gain for Long-Term Debt Issuances was 6600.0% in 2018; the steepest drop was 120.0% in 2018.
  • Harvard Bioscience's Long-Term Debt Issuances stood at $500000.0 in 2017, then crashed by 120.0% to -$100000.0 in 2018, then soared by 2100.0% to $2.0 million in 2019, then surged by 2485.0% to $51.7 million in 2020, then plummeted by 96.62% to $1.8 million in 2021.
  • Per Business Quant, the three most recent readings for HBIO's Long-Term Debt Issuances are $1.8 million (Q4 2021), $2.5 million (Q3 2021), and $51.7 million (Q4 2020).